Please login to the form below
polidocanol
This page shows the latest polidocanol news and features for those working in and with pharma, biotech and healthcare.
BTG rises on FDA approval of varicose vein therapy
Varithena (polidocanol) - formerly known as Varisolve - has been tipped by the company as having the potential to make up to $500m in annual sales at peak, thanks to advantages over current ... that polidocanol might escape into the bloodstream.
Latest news
-
Slim pickings
India. Pioglitazone . Actos OD (Takeda). Type 2 diabetes mellitus . Japan. Polidocanol .
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
PMHub
M3 (EU)
M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
